Zuranolone In Major Depressive Disorder: Interim Efficacy Results From A Phase 3, Open-Label, Longitudinal Study

Andrew Cutler,Scott T. Aaronson,Gregory W. Mattingly,Samuel T. Wilkinson,Robert Lasser,Indrani Nandy,Brian Werneburg,Jeffrey Jonas,Stephen J. Kanes,Timothy Mariano

BIOLOGICAL PSYCHIATRY（2021）

引用 0|浏览3

暂无评分

摘要

Zuranolone is an oral neuroactive steroid under investigation as a treatment for major depressive disorder (MDD). This ongoing Phase 3, open-label, 1-year longitudinal study is evaluating the safety, tolerability, and need for retreatment with zuranolone in patients with MDD.

查看译文

关键词

Zuranolone, Major Depressive Disorder (MDD), Neuroactive Steroid

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要